Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.61 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25377106 | 0.98 | PNMT (0.59) | PNMTPRCPTRPM5ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL31264082 | 0.98 | PNMT (0.59) | PNMTPRCPTRPM5ADRA2AADRA2B | |
| SCHEMBL8326838 | 0.83 | PNMT (0.57) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL8326841 | 0.83 | PNMT (0.57) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL25377761 | 0.83 | PNMT (0.57) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL31264062 | 0.83 | PNMT (0.57) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL14355729 | 0.81 | PNMT (0.69) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL172636 | 0.81 | PNMT (0.69) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL13453377 | 0.81 | PNMT (0.69) | PNMTPRCPADRA2AADRA2BADRA2C | |
| SCHEMBL8853554 | 0.79 | PNMT (0.71) | PNMTPRCPADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469041-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-10-22 | — | — | US | claimed |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | claimed |
| EP-0941223-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-15 | — | — | EP | claimed |
| US-5760225-A | DIAGNOSIS AND TREATMENT OF STRESS DISORDERS AND DEPRESSION | NEUROGEN CORPORATION (US) | 1998-06-02 | — | — | US | claimed |
| WO-1998021200-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-05-22 | — | — | WO | claimed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150105547-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2015-04-16 | — | — | US | disclosed |
| US-8933062-B2 | Nitric oxide releasing steroids | NICOX S.A. (FR) | 2015-01-13 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20100234334-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20100093685-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. | 2010-04-15 | — | — | US | disclosed |
| US-6469041-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6300360-B1 | FOR THERAPY OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6127399-A | TREATING POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5973152-A | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION | 1999-10-26 | — | — | US | disclosed |
| EP-0941223-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5760225-A | DIAGNOSIS AND TREATMENT OF STRESS DISORDERS AND DEPRESSION | NEUROGEN CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998021200-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105547-A1 | NITRIC OXIDE RELEASING STEROIDS | NR3C1, CYP11B1, NOS1 | PNMT 2425/4885PRCP 3476/4885TRPM5 3772/4885 |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | PNMT 4542/4885PRCP 2346/4885TRPM5 3322/4885 |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | CRH, CRHR1, CRHR2 | PNMT 1817/4885PRCP 499/4885TRPM5 838/4885 |
| US-20100093685-A1 | NITRIC OXIDE RELEASING STEROIDS | NR3C1, CYP11B1, NOS1 | PNMT 2460/4885PRCP 3216/4885TRPM5 4173/4885 |
| US-20100234334-A1 | NITRIC OXIDE RELEASING STEROIDS | NOS1, NR3C1, NOS2 | PNMT 1237/4885PRCP 3618/4885TRPM5 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.